Search

Your search keyword '"Tanderup, K"' showing total 807 results
Start Over Author "Tanderup, K"
807 results on '"Tanderup, K"'

5. Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging – An analysis from the EMBRACE study

Author

Knoth, J., Pötter, R., Jürgenliemk-Schulz, I.M., Haie-Meder, C., Fokdal, L., Sturdza, A., Hoskin, P., Mahantshetty, U., Segedin, B., Bruheim, K., Wiebe, E., Rai, B., Cooper, R., van der Steen-Banasik, E., van Limbergen, E., Pieters, B.R., Sundset, M., Tan, L.T., Nout, R.A., Tanderup, K., Kirisits, C., Nesvacil, N., Lindegaard, J.C., and Schmid, M.P.

Published
2020
Full Text
View/download PDF

8. Association between Regular Vaginal Dilation and/or Sexual Activity and Long-Term Vaginal Morbidity in Cervical Cancer Survivors

Author

Kirchheiner, K., primary, Zaharie, A.T., additional, Smet, S., additional, Spampinato, S., additional, Chargari, C., additional, Mahantshetty, U.M., additional, Segedin, B., additional, Bruheim, K., additional, Rai, B., additional, Cooper, R., additional, Van der Steen-Banasik, E., additional, Wiebe, E.M., additional, Potter, R., additional, Kirisits, C., additional, Schmid, M., additional, Haie-Meder, C., additional, Tanderup, K., additional, De Leeuw, A., additional, Jurgenliemk-Schulz, I., additional, and Nout, R.A., additional

Published
2023
Full Text
View/download PDF

13. OC-0129 Impact of brachytherapy applicator on morbidity and local control in cervix cancer: EMBRACE study

Author

Serban, M., primary, Spampinato, S., additional, de Leeuw, A., additional, Fortin, I., additional, Nevascil, N., additional, Kirisits, C., additional, Schmid, M., additional, Mahantshetty, U., additional, Hoskin, P., additional, Segedin, B., additional, Bruheim, K., additional, Huang, F., additional, Pieters, B., additional, Nout, R., additional, Pötter, R., additional, Kirchheiner, K., additional, Jürgenliemk-Schulz, I., additional, and Tanderup, K., additional

Published
2023
Full Text
View/download PDF

16. Patient-reported sexual frequency and vaginal functioning in patients with locally advanced cervical cancer following definitive radiochemotherapy and image-guided adaptive brachytherapy (EMBRACE study)

Author

Kirchheiner, K, Jürgenliemk-Schulz, I M, Haie-Meder, C, Lindegaard, J C, Sturdza, A, Mahantshetty, U, Segedin, B, Bruheim, K, Rai, B, Cooper, R, van der Steen-Banasik, E, Wiebe, E, Sundset, M, van Limbergen, E, Villafranca, E, Westerveld, H, Tan, L T, Tanderup, K, Pötter, R, and Nout, R A

Published
2019
Full Text
View/download PDF

20. Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy

Author

MS Radiotherapie, Cancer, Suvaal, I, Kirchheiner, K, Nout, R A, Sturdza, A E, Van Limbergen, E, Lindegaard, J C, Putter, H, Jürgenliemk-Schulz, I M, Chargari, C, Tanderup, K, Pötter, R, Creutzberg, C L, Ter Kuile, M M, MS Radiotherapie, Cancer, Suvaal, I, Kirchheiner, K, Nout, R A, Sturdza, A E, Van Limbergen, E, Lindegaard, J C, Putter, H, Jürgenliemk-Schulz, I M, Chargari, C, Tanderup, K, Pötter, R, Creutzberg, C L, and Ter Kuile, M M

Published
2023

23. OC-0503 Effect of dose and fractionation de-escalation in low-risk cervix cancer treated with EBRT and BT

Author

Serban, M., Gallois, M., Urtubey, T., Nout, R., de Leeuw, A., Fokdal, L., Assenholt, M., Spampinato, S., Bruheim, K., Segedin, B., Chopra, S., Schmid, M., Nesvacil, N., Ecker, S., Kirchheiner, K., Pötter, R., Westerveld, H., Huang, F., Velema, L., Tan, L.T., Valgma, M., Mathiesen, H., Lindegaard, J., Jürgenliemk-Schulz, I., and Tanderup, K.

Published
2022
Full Text
View/download PDF

27. OC-0830 Systemic recurrence after primary chemoradiation in cervical cancer patients – an EMBRACE analysis

Author

Knoth, J., primary, Nout, R., additional, Mahantshetty, U., additional, Jürgenliemk-Schulz, I., additional, Haie-Meder, C., additional, Fokdal, L.U., additional, Sturdza, A., additional, Hoskin, P., additional, Segedin, B., additional, Bruheim, K., additional, Huang, F., additional, Rai, B., additional, Cooper, R., additional, van der Steen-Banasik, E., additional, van Limbergen, E., additional, Pieters, B.R., additional, Tan, L.T., additional, Kannan, S., additional, de Leeuw, A.A., additional, Nesvacil, N., additional, Tanderup, K., additional, Kirisits, C., additional, Lindegaard, J.C., additional, Pötter, R., additional, and Schmid, M.P., additional

Published
2022
Full Text
View/download PDF

28. PO-1801 Primary standards and measurement methods for X-ray emitting electronic BT devices PRISM-eBT

Author

Schneider, T., primary, Behrens, R., additional, Garcia-Yip, F., additional, Tanderup, K., additional, Kertzscher, G., additional, Johanson, J., additional, Georgi, P., additional, Blideanu, V., additional, Stien, C., additional, Plagnard, J., additional, Solc, J., additional, Sochor, V., additional, Pinto, M., additional, Sander, T., additional, Subiel, A., additional, Gouldstone, C., additional, de Prez, L., additional, Verhaegen, F., additional, Reniers, B., additional, Avilés Lucas, P., additional, Msimang, Z., additional, Eaton, D.J., additional, Weigand, F., additional, and Rivard, M.J., additional

Published
2022
Full Text
View/download PDF

30. OC-0443 3D-Image-guided brachytherapy plus irradiation in stage-I-III inoperable endometrial cancer.

Author

Rovirosa, A., primary, Zhang, Y., additional, Chargari, C., additional, Van der Steen-Banasik, E., additional, Wojcieszek, P., additional, Stankiewicz, M., additional, Najjari, D., additional, Hoskin, P., additional, Han, K., additional, Segedin, B., additional, Potter, R., additional, Tanderup, K., additional, and Van Limbergen, E., additional

Published
2022
Full Text
View/download PDF

31. OC-0588 Impact of persistent symptoms on long-term quality of life of cervical cancer survivors in EMBRACE I

Author

Spampinato, S., primary, Tanderup, K., additional, Nout, R., additional, Smet, S., additional, Lindegaard, J.C., additional, Fokdal, L.U., additional, Pötter, R., additional, Sturdza, A., additional, Segedin, B., additional, Jürgenliemk-Schulz, I., additional, Bruheim, K., additional, Mahantshetty, U., additional, Chargari, C., additional, Rai, B., additional, Cooper, R., additional, van der Steen-Banasik, E., additional, Sundset, M., additional, Wiebe, E., additional, Villafranca, E., additional, Van Limbergen, E., additional, Chopra, S., additional, and Kirchheiner, K., additional

Published
2022
Full Text
View/download PDF

33. 3D Image-Guided Brachytherapy as Only Treatment for Stage-I Inoperable Endometrial Cancer: Retrospective Analysis of the Gynecological Cancer GEC-ESTRO Working Group

Author

Rovirosa, A., primary, Zhang, Y., additional, Chargari, C., additional, Cooper, R., additional, Wojcieszek, P., additional, Stankiewicz, M., additional, Hoskin, P., additional, van der Steen-Banas, E., additional, Segedin, B., additional, Najjari, D., additional, Potter, R., additional, Tanderup, K., additional, and van Limbergen, E., additional

Published
2021
Full Text
View/download PDF

36. OC-0025 Tumor regression of cervical cancer during chemoradiation evaluated by the T-score in EMBRACE I

Author

Lindegaard, J.C., Petric, P., Schmid, M.P., Haie-Meder, C., Fokdal, L.U., Sturdza, A., Hoskin, P., Mahantshetty, U., Segedin, B., Bruheim, K., Huang, F., Rai, B., Cooper, R., van der Steen-Banasik, E., Van Limbergen, E., Pieters, B.R., Tan, L.T., Nout, R., de Leeuw, A., Nesvacil, N., Kirchheiner, K., Jürgenliemk-Schultz, I., Tanderup, K., Kirisits, C., Pötter, R., and Collaborative Group, E.

Published
2021
Full Text
View/download PDF

37. Importance of training in external beam treatment planning for locally advanced cervix cancer

Author

Seppenwoolde, Y., Assenholt, M.S., Georg, D., Nout, R., Tan, L.T., Rumpold, T., Leeuw, A. de, Jurgenliemk-Schulz, I., Kirisits, C., Potter, R., Lindegaard, J.C., Tanderup, K., EMBRACE Collaborative Grp, and Radiotherapy

Subjects
medicine.medical_specialty, Dummy run, Computer science, medicine.medical_treatment, Brachytherapy, Uterine Cervical Neoplasms, Plan (drawing), EBRT treatment planning, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, medicine, Humans, Radiology, Nuclear Medicine and imaging, Medical physics, External beam radiotherapy, EMBRACE II, Radiation treatment planning, QA, Accreditation, Protocol (science), Contouring, Radiotherapy Planning, Computer-Assisted, Radiotherapy Dosage, Hematology, 3. Good health, Oncology, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Female, Median body, Lymph Nodes, Radiotherapy, Image-Guided
Abstract

Background and purpose: The EMBRACE II study combines state-of-the-art Image-Guided Adaptive Brachytherapy in cervix cancer with an advanced protocol for external beam radiotherapy (EBRT) which specifies target volume selection, contouring and treatment planning. In EMBRACE II, well-defined EBRT is an integral part of the overall treatment strategy with the primary aim of improving nodal control and reducing morbidity. The EMBRACE II EBRT planning concept is based on improved conformality through relaxed coverage criteria for all target volumes. For boosting of lymph nodes, a simultaneous integrated boost and coverage probability planning is applied. Before entering EMBRACE II, institutes had to go through accreditation. Material and methods: As part of accreditation, a treatment planning dummy-run included educational blocks and submission of an examination case provided by the study coordinators. Seventy-one centers submitted 123 EBRT dose distributions. Replanning was required if hard constraints were violated or planning concepts were not fully accomplished. Dosimetric parameters of original and revised plans were compared. Results: Only 11 plans violated hard constraints. Twenty-seven centers passed after first submission. 27 needed one and 13 centers needed more revisions. The most common reasons for revisions were low conformality, relatively high OAR doses or insufficient lymph node coverage reduction. Individual feedback on planning concepts improved plan quality considerably, resulting in a median body V43Gy reduction of 158 cm 3 from first plan submission to approved plan. Conclusion: A dummy-run as applied in EMBRACE II, consisting of training and examination cases enabled us to test institutes’ treatment planning capabilities, and improve plan quality.

Published
2019
Full Text
View/download PDF

41. OC-0296 Risk factors for severe gastrointestinal morbidity in locally advanced cervix cancer (EMBRACE study)

Author

Spampinato, S., primary, Jensen, N.B., additional, Fokdal, L.U., additional, Pötter, R., additional, Haie-Meder, C., additional, Lindegaard, J.C., additional, Schmid, M.P., additional, Sturdza, A., additional, Jürgenliemk-Schulz, I.M., additional, Mahantshetty, U., additional, Segedin, B., additional, Hoskin, P., additional, Bruheim, K., additional, Rai, B., additional, Wiebe, E., additional, Cooper, R., additional, van der Steen-Banasik, E., additional, Van Limbergen, E., additional, Kirisits, C., additional, Nout, R.A., additional, Chopra, S., additional, Kirchheiner, K., additional, and Tanderup, K., additional

Published
2021
Full Text
View/download PDF

43. OC-0295 New Prognostic factors in locally advanced cervical cancer treated with MR-IGABT in EMBRACE Study.

Author

Mahantshetty, U., primary, Schmid, M., additional, Kirisits, C., additional, Tanderup, K., additional, Haie-Meder, C., additional, Fokdal, L., additional, Sturdza, A., additional, Hoskin, P., additional, Segredin, B., additional, Bruheim, K., additional, Huang, F., additional, Rai, B., additional, Cooper, R., additional, van der Steen-Banasik, E., additional, van Limbergen, E., additional, Pieters, B., additional, Tan, L.T., additional, Hawaldar, R., additional, Kannan, S., additional, Nout, R., additional, de Leeuw, A.A.C., additional, Nesvacil, N., additional, Jürgenliemk-Schulz, I., additional, Lindegaard, J., additional, and Pötter, R., additional

Published
2021
Full Text
View/download PDF

45. PO-1487 Brachytherapy training survey among Radiation Oncology residents in Europe

Author

Sturdza, A., primary, Stephanides, M., additional, Eriksen, J.G., additional, Benstead, K., additional, Hoskin, P., additional, Vlad, S., additional, Escande, A., additional, Corradini, S., additional, Konrad, S., additional, Westerveld, H., additional, Tagliaferri, L., additional, Najjari, D., additional, Konat-Bąska, K., additional, Plesinac Karapandzic, V., additional, Tan, L.T., additional, Nout, R., additional, Peters, B., additional, Tanderup, K., additional, Jürgenliemk-Schulz, I., additional, and Kamrava, M., additional

Published
2021
Full Text
View/download PDF

47. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

Author

Pötter R., Tanderup K., Schmid M.P., Jürgenliemk-Schulz I., Haie-Meder C., Fokdal L.U., Sturdza A.E., Hoskin P., Mahantshetty U., Segedin B., Bruheim K., Huang F., Rai B., Cooper R., van der Steen-Banasik E., Van Limbergen E., Pieters B.R., Tan L.-T., Nout R.A., De Leeuw A.A.C., Ristl R., Petric P., Nesvacil N., Kirchheiner K., Kirisits C., Lindegaard J.C., Chargari C., Dumas I., Lowe G., Swamidas J., Hudej R., Paulsen Hellebust T., Menon G., Oinam A.S., Bownes P., Christiaens M., De Brabandere M., Janssen H., Oosterveld B., Koedooder K., Langeland Marthinsen A.B., Sundset M., Whitney D., Ketelaars M., Lutgens L.C.H.W., Reinniers B., Mora I., Villafranca E., Antal G., Hadjiev J., Bachand F., Batchelar D., Erickson B., Rownd J., Jacobson G., Kim Y., Anttila M., Palmgren J.-E., An J., Assenholt M.S., Banerjee S., Bentzen S., Berger T., Dankulchai P., Diendorfer T., Dilworth I., Dimopoulos J., Dörr E., Ecker S., Federico M., Fidarova E., Fortin I., Georg P., Gora J., Hegazy N., Jastaniyah N., Jensen N.B.K., Liederer T., Majercakova K., Misimovic D., Motisi L., Najjari Jamal D., Nkiwane K., Schwartz-Vittrup A., Serban M., Smet S., Spampinato S., Trnkova P., Valgma M., Westerveld H., Wong J.S.Y., Yoshida K., and EMBRACE Collaborative Group

Subjects
Asia, diagnostic imaging, Brachytherapy, cisplatin, uterine cervix carcinoma, morbidity, image guided radiotherapy, external beam radiotherapy, Article, Disease-Free Survival, multiple cycle treatment, chemoradiotherapy, volumetric modulated arc therapy, cancer control, fistula, follow up, urogenital tract disease, International Federation of Gynecology and Obstetrics, uterine cervix tumor, human, procedures, nuclear magnetic resonance imaging, outcome assessment, disease free survival, lymph node metastasis, cancer staging, adult, clinical trial, cohort analysis, major clinical study, intensity modulated radiation therapy, Europe, aged, multicenter study, female, quality of life, priority journal, North America, observational study, pathology, conformal radiotherapy, radiation dose, image guided adaptive brachytherapy, uterine cervix cancer, prospective study
Abstract

Background: The concept of the use of MRI for image-guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer was introduced 20 years ago. Here, we report on EMBRACE-I, which aimed to evaluate local tumour control and morbidity after chemoradiotherapy and MRI-based IGABT. Methods: EMBRACE-I was a prospective, observational, multicentre cohort study. Data from patients from 24 centres in Europe, Asia, and North America were prospectively collected. The inclusion criteria were patients older than 18 years, with biopsy-proven squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, The International Federation of Gynecology and Obstetrics (FIGO) stage IB–IVA disease or FIGO stage IVB disease restricted to paraaortic lymph metastasis below the L1–L2 interspace, suitable for curative treatment. Treatment consisted of chemoradiotherapy (weekly intravenous cisplatin 40 mg/m2, 5–6 cycles, 1 day per cycle, plus 45–50 Gy external-beam radiotherapy delivered in 1·8–2 Gy fractions) followed by MRI-based IGABT. The MRI-based IGABT target volume definition and dose reporting was according to Groupe Européen de Curiethérapie European Society for Radiation Oncology recommendations. IGABT dose prescription was open according to institutional practice. Local control and late morbidity were selected as primary endpoints in all patients available for analysis. The study was registered with ClinicalTrials.gov, NCT00920920. Findings: Patient accrual began on July 30, 2008, and closed on Dec 29, 2015. A total of 1416 patients were registered in the database. After exclusion for not meeting patient selection criteria before treatment, being registered but not entered in the database, meeting the exclusion criteria, and being falsely excluded, data from 1341 patients were available for analysis of disease and data from 1251 patients were available for assessment of morbidity outcome. MRI-based IGABT including dose optimisation was done in 1317 (98·2%) of 1341 patients. Median high-risk clinical target volume was 28 cm3 (IQR 20–40) and median minimal dose to 90% of the clinical target volume (D90%) was 90 Gy (IQR 85–94) equi-effective dose in 2 Gy per fraction. At a median follow-up of 51 months (IQR 20–64), actuarial overall 5-year local control was 92% (95% CI 90–93). Actuarial cumulative 5-year incidence of grade 3–5 morbidity was 6·8% (95% CI 5·4–8·6) for genitourinary events, 8·5% (6·9–10·6) for gastrointestinal events, 5·7% (4·3–7·6) for vaginal events, and 3·2% (2·2–4·5) for fistulae. Interpretation: Chemoradiotherapy and MRI-based IGABT result in effective and stable long-term local control across all stages of locally advanced cervical cancer, with a limited severe morbidity per organ. These results represent a positive breakthrough in the treatment of locally advanced cervical cancer, which might be used as a benchmark for clinical practice and all future studies. Funding: Medical University of Vienna, Aarhus University Hospital, Elekta AB, and Varian Medical Systems. © 2021 Elsevier Ltd

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results